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ABSTRACT
Background: Vitamin B-6 homeostasis is altered during inflamma-
tion and immune activation. It is unknown whether altered vitamin
B-6 homeostasis is associated with the risk of stroke.
Objective: We investigated the relation between the ratio plasma 4-
pyridoxic acid: (pyridoxal + pyridoxal-5′-phosphate) (PAr) as an in-
dicator of altered vitamin B-6 homeostasis and the risk of stroke in
the general population.
Design: We conducted a prospective analysis of the community-
based Hordaland Health Study (HUSK) in 6891 adults (born dur-
ing 1925–1927 and 1950–1951) without known stroke at base-
line (1998–1999). Participants were followed via linkage to the
CVDNOR (Cardiovascular Disease in Norway) project and the
Cause of Death Registry. HRs and 95% CIs were calculated using
Cox proportional hazards analyses.
Results: A total of 390 participants (193 men and 197 women) de-
veloped stroke over a median follow-up period of 11 y. Study partic-
ipants with elevated PAr experienced a higher risk of incident stroke
in an essentially linear dose-response fashion. The HR (95% CI)
for the highest compared with the lowest quartile of PAr was 1.97
(1.42, 2.73; P-trend <0.001) for total stroke and 2.09 (1.42, 3.09; P-
trend<0.001) for ischemic stroke after adjustment for age, sex, body
mass index (BMI), smoking, education, physical activity, estimated
glomerular filtration rate, hypertension, diabetes, total cholesterol,
and statin use. PAr had greater predictive strength than did C-reactive
protein, current smoking, diabetes, hypertension, estimated glomeru-
lar filtration rate, and physical activity. The associations were similar
in subgroups stratified by age group, sex, BMI, current smoking, hy-
pertension, diabetes, and statin use at baseline.
Conclusions:Higher plasma PAr was independently associated with
increased risk of incident stroke in all participants and across all sub-
groups stratified by conventional risk predictors. Our novel findings
point to and expand the range of inflammation and immune activa-
tion processes that may be relevant for the pathogenesis and pre-
vention of stroke. This trial was registered at clinicaltrials.gov as
NCT03013725. Am J Clin Nutr 2018;107:105–112.
Keywords: vitamin B-6, biomarker, stroke, inflammation, cohort,
risk
INTRODUCTION
Stroke is the second most common cause of death worldwide
and a major cause of serious long-term disability (1). About 80%
of all strokes are ischemic (2). In the past few decades, significant
advances have been made in the identification and treatment of
conventional risk factors, including high blood pressure, diabetes,
smoking, and physical inactivity (3). However, only 60–80% of
ischemic strokes may be attributed to these factors (4), a finding
that has motivated a search for novel risk factors.
Chronic inflammation has been suggested to be involved in the
development of stroke (5). For example, the commonly used in-
flammatory marker C-reactive protein (CRP) has been linked to
ischemic stroke, although results from individual studies are in-
consistent (6, 7). Neopterin, a marker of cellular immunity acti-
vation, has been related to prognostic outcome andmortality after
stroke (8, 9).
Vitamin B-6 has attracted attention because of its widespread
involvement in the body metabolism and function (10). The ma-
jor circulating B-6 vitamers include the active form pyridoxal-5′-
phosphate (PLP), the transport form pyridoxal, and the catabolite
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4-pyridoxic acid (PA) (11, 12). There are consistent reports on
the inverse associations of low plasma PLP with markers of in-
flammation and clinical conditions linked to low-grade inflamma-
tion, including cardiovascular disease and stroke (12). Recently,
we proposed the PA:(PLP + pyridoxal) ratio (PAr), as a possible
marker of altered vitamin B-6 homeostasis during cellular im-
mune activation (11, 13). Key properties of PLP-catabolizing en-
zymes indicate a plausible association of high PAr with aldehyde
and oxidative stress (13). Furthermore, the acute inflammatory
response (as indicated by, for example, CRP) was found to be as-
sociated with a redistribution of PLP from the plasma to other
tissues (14), thereby linking elevated PAr to other inflammatory
modalities as well.
Recent observations demonstrate that PAr predicts the risk of
inflammatory-related conditions including cancer (15), especially
lung (15) and colorectal cancer (16), as well as long-term mor-
tality in patients with coronary artery disease (17). However, no
published studies, to our knowledge, have explored a possible as-
sociation of PAr with stroke.
We therefore tested the hypothesis that altered vitamin B-6
homeostasis during inflammation and immune activation, cap-
tured by plasma PAr, predicts long-term risk of cerebral stroke
in a prospective cohort of community-dwelling adults.
METHODS
Study population
The Hordaland Health Study (HUSK) is a community-based
study with baseline measurements and survey conducted during
1997–1999 as collaboration between the University of Bergen,
the National Institute of Public Health, and the Municipal Health
Service in Hordaland, Western Norway (http://husk.b.uib.no).
The Regional Committee forMedical andHealth Research Ethics
in Western Norway (REK-Vest) approved the study protocol.
Written informed consent was obtained from all participants. De-
tails of the study design and methodology have been described
elsewhere (18, 19). The source population in the current study
was 17,361 participants born during 1925–1927 and 1950–1951
and living in the city of Bergen and its surrounding areas who
participated in the Hordaland Homocysteine Study in 1992–1993
(19). Of these, 9187 participants were invited to the HUSK study,
and a total of 7074 participants met for physical examinations
and completed self-administered questionnaires (19), yielding a
participation rate of 77%. The present study cohort comprised
7050 men and women who donated blood samples. Of these, 67
were excluded due to hospitalization with stroke before enroll-
ment, and 92 with missing data on plasma measurements of PLP,
pyridoxal or PA. This left 6891 participants (3036 men and 3855
women) in the final study cohort, as described in Figure 1.
Biochemical analyses
Non-fasting plasma specimens were collected at baseline and
stored at –80°C until analysis. Plasma PLP, pyridoxal, PA,
neopterin, and cotinine were measured using liquid chromatog-
raphy/tandem mass spectrometry (20). In addition, serum total
cholesterol was measured using standard methods and creati-
nine measured colorimetrically using the alkaline picrate method
(18). Plasma high-sensitivity CRP was measured by an immuno-
matrix-assisted laser desorption/ionization mass spectrometry
assay (21). All biochemical analyses were performed at Bevital
A/S, Bergen (www.bevital.no), except for serum total cholesterol
and creatinine which were analyzed at Ullevål University Hospi-
tal, Oslo. The coefficients of variation for PLP, pyridoxal, PA, and
neopterin were 2.8–3.7% (within-day) and 5.7–7.1% (between-
day) (20).
Follow-up and outcome ascertainment
The cohort participants were followed from baseline to the date
of stroke diagnosis, death, emigration, or 31 December 2009 (the
end of follow-up), whichever came first. Follow-up was 100%
complete with a total of 70,662 person-years. Stroke cases were
ascertained via record linkage to national hospital discharge diag-
noses data obtained through the Cardiovascular Disease in Nor-
way (CVDNOR) project, 1994–2009 (www.cvdnor.no) (22–24).
The primary outcome was hospitalization or death attributed
to stroke [total stroke: International Classification of Diseases
(ICD)-9 codes 430–434, 436 and ICD-10 codes I60–I61, I63–I64
except I63.6; ischemic stroke: ICD-9 codes 433, 434 and ICD-10
codes I63 except I63.6]. Information on death was collected from
the Cause of Death Registry at Statistics Norway and coded ac-
cording to ICD-10. If >1 stroke event occurred in a participant
during the follow-up period, only the first event was considered.
An 11-digit personal identifier, unique to each Norwegian resi-
dent, was used to link baseline variables with study endpoints.
Assessments of covariates
Information on education (highest level of completed educa-
tion), physical activity, statin use, and a history of coronary heart
disease (CHD, defined as myocardial infarction or angina pec-
toris) at baseline was collected via self-administered question-
naires. Height and weight were measured and BMI was calcu-
lated as weight in kilograms divided by height in meters squared.
Smoking status was based on self-reported smoking status and
corrected by plasma cotinine (i.e., self-reported nonsmokers with
plasma cotinine concentrations ≥85 nmol/L were reclassified as
current smokers) (25). Participants were considered to have hy-
pertension at baseline if they reported use of antihypertensive
medication or had a blood pressure ≥140/90 mm Hg (26). Di-
abetes was defined based on self-reported diabetes, use of hypo-
glycemic medication, or blood glucose concentration at baseline
(27). Calculation of estimated glomerular filtration rate (eGFR)
was based on serum creatinine concentrations using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) equa-
tion (28). Vitamin B-6 supplementation was assessed by a
validated self-administered food frequency questionnaire (29).
Fasting was defined as no caloric intake for ≥8 h.
Statistical analysis
Since PAr levels were markedly higher in the older age group
(median: 0.46 for 70–74 y compared with 0.34 for 46–49 y), age-
specific quartiles were defined for the 2 age groups separately.
Baseline characteristics of study participants are described for
all participants combined and according to quartiles of PAr, and
variables are expressed as percentages or medians (interquartile
ranges). Trends across quartiles were tested by logistic and quan-
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A total of 17,361 participants from 
the Hordaland Homocysteine Study 
1992-1993
Not invited due to financial 
limitation (n = 8174) 
Met for physical examinations and 
completed questionnaires (n = 7074) 
Born 1950-1951 (n = 3733) 
Born 1925-1927 (n = 3341) 
Donated blood samples (n = 7050) 
Born 1950-1951 (n = 3723) 
Born 1925-1927 (n = 3327)
Final study cohort (n = 6891, 
3036 men and 3855 women) 
Born 1950-1951 (n = 3655) 
Born 1925-1927 (n = 3236)
Excluded (n = 159) 
Hospitalization with stroke before 
enrollment (n = 67) 
No data on plasma measurements 
of PLP, pyridoxal or PA (n = 92) 
Total invited (n = 9187) 
Born 1950-1951 (n = 4849) 
Born 1925-1927 (n = 4338)
FIGURE 1 Flow chart of study participants. PA, 4-pyridoxic acid; PAr, 4-pyridoxic acid/(pyridoxal + pyridoxal-5′-phosphate).
respectively. Natural log transformation was applied to plasma
biomarkers to normalize distributions.
We used Cox proportional hazards regression to evaluate PAr
and long-term stroke risk. HRs and corresponding 95% CIs
are reported per 1-SD increment. To estimate the independent
association of PAr with risk of stroke (total and ischemic stroke,
respectively), 3 multivariate models were constructed: model
1 was the basic model adjusted for age (46–49 compared with
70–74 y) and sex; model 2 was adjusted as model 1 plus lifestyle
risk factors—BMI (continuous), current smoking (yes or no), ed-
ucation (≤10, 11–13, or ≥14 y) and physical activity (none/light
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TABLE 1
Baseline characteristics of all participants and by PAr quartiles in the HUSK1
PAr quartile
Characteristic All Q1 Q2 Q3 Q4 P-trend2 P-trend3
Participants, n 6891 1722 1723 1723 1723
Men, % 44.1 46.4 46.3 43.6 39.9 <0.001 <0.001
BMI, kg/m2 25.4 (23.1, 27.9) 25.5 (23.3, 27.8) 25.6 (23.3, 28.1) 25.2 (23.0, 27.9) 25.1 (22.8, 27.9) 0.002 0.02
Current smoking, % 28.7 23.6 27.0 29.4 34.6 <0.001 <0.001
Physical activity, %
None/light 43.6 43.3 41.9 43.9 45.3 0.14 0.35
Moderate/vigorous 56.4 56.7 58.1 56.1 54.7
Education, y
≤10 31.1 30.1 31.1 33.3 29.6
11–13 40.8 41.1 40.5 39.5 42.2 0.67 0.57
≥14 28.1 28.8 28.4 27.2 28.2
eGFR, mL · min−1 · 1.73 m−2 79.9 (69.0, 89.8) 82.3 (71.8, 92.4) 80.6 (70.3, 90.3) 79.3 (68.6, 88.9) 77.0 (66.0, 87.7) <0.001 <0.001
Hypertension, % 42.3 40.9 41.7 43.2 43.5 0.08 0.04
Diabetes, % 2.7 2.0 2.4 3.3 2.8 0.06 0.07
Total cholesterol, mmol/L 5.9 (5.2, 6.7) 6.0 (5.3, 6.8) 6.0 (5.3, 6.7) 6.0 (5.2, 6.7) 5.7 (5.1, 6.5) <0.001 <0.001
Statin use, % 7.2 7.0 7.7 6.9 7.0 0.72 0.65
History of CHD, % 8.3 6.5 8.1 8.5 10.0 <0.001 <0.001
Plasma biomarkers
PAr 0.39 (0.29, 0.52) 0.24 (0.21, 0.29) 0.33 (0.30, 0.40) 0.43 (0.38, 0.51) 0.66 (0.53, 0.82)
CRP, mg/L 1.6 (0.7, 3.6) 1.2 (0.6, 2.4) 1.4 (0.6, 3.1) 1.7 (0.7, 3.9) 2.1 (0.9, 5.4) <0.001 <0.001
Neopterin, nmol/L 7.6 (6.4, 9.3) 7.0 (6.0, 8.3) 7.4 (6.2, 9.0) 7.8 (6.6, 9.4) 8.4 (7.0, 10.7) <0.001 <0.001
1Values are presented as medians (IQRs) or percentages. CRP, C-reactive protein; CHD, coronary heart disease; eGFR, estimated glomerular filtration
rate; HUSK, Hordaland Health Study; PAr, 4-pyridoxic acid/(pyridoxal + pyridoxal-5′-phosphate); Q, quartile.
2Derived from logistic regression for categorical variables and quantile (median) regression for continuous variables, unadjusted.
3Adjusted for sex.
potential mediators—eGFR (continuous), hypertension (yes or
no), diabetes (yes or no), total cholesterol (continuous), and statin
use (yes or no). In addition, we also assessed the associations
after additional adjustment for CRP (continuous), neopterin
(continuous), vitamin B-6 supplementation (yes or no), and
fasting status (yes or no) in the models. The proportionality
assumption was tested using Schoenfeld residuals. To test for
potential confounding or mediation by plasma CRP or neopterin,
we also examined the associations by additional adjustment
for these 2 biomarkers. Potential nonlinear associations of PAr
levels with stroke risk were modeled by generalized additive
models using penalized splines with multivariable adjustment as
indicated in model 3 (30). To corroborate the findings, the risk
associations were also evaluated across age-specific quartiles of
PAr, and P-trend was calculated by modeling the quartile number
as a continuous variable in the regression models.
Potential effect modification by age group, sex, BMI (below
or above median), current smoking, hypertension, diabetes, and
statin use was assessed in stratified analyses and significance
of interactions was assessed based on first-degree multiplica-
tive models for each stratification variable separately. Sensitivity
analyses were performed to determine the robustness of findings
in the primary analysis. We restricted the risk-association anal-
yses to participants who had no self-reported history of CHD or
stroke at baseline. In addition, the analyses were repeated after
excluding the first 2 y of follow-up.
We performed forward and backward stepwise selection of
predictors, keeping age and sex as adjustments at all times using
the R-package crrstep (31). The impact on the model fit from the
addition or removal of predictors was evaluated with the use of
the modified Bayesian information criterion for competing risk
as recommended by the developers of the package (31). To as-
sess improvement in model discrimination and reclassification of
the study participants, we calculated the integrated discrimina-
tion index and the continuous net reclassification index (>0) in
logistic regression models containing the same covariates as the
multivariate Cox model, with and without PAr (32, 33).
Statistical analyses were conducted with the SAS statistical
software (version 9.4; SAS Institute, Inc.) and R (version 3.4.0,
www.r-project.org). All tests were 2 sided and a P value <0.05
was considered statistically significant.
RESULTS
Among the 6891 participants, a total of 390 (193 men and
197 women) developed stroke over a median follow-up period of
10.9 y (range: 0.1–11.7 y), of which 279 (72%) were ischemic.
Baseline characteristics of the study participants as a whole and
trends across quartiles of PAr are shown in Table 1. Participants
in higher PAr quartiles were more likely to be women, current
smokers (P < 0.001), and to have hypertension, diabetes, and a
history of CHD at baseline. PAr levels were inversely associated
with BMI, eGFR, and total cholesterol concentrations. As ex-
pected, PAr was positively associated with the plasma biomarkers
CRP (P < 0.001) and neopterin (P < 0.001) at baseline. In ad-
dition, use of vitamin B-6 supplements was a weak predictor of
PAr, whereas it was an important predictor of PLP, pyridoxal, and
PA. Fasting status contributed no additional explained variation
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TABLE 2
HRs (95% CI) for risk of total and ischemic stroke by PAr in the HUSK1
PAr quartile Continuous
Q1 Q2 Q3 Q4 P-trend
Per 1-SD increment
of log-transformed PAr P
Total stroke
Cases/n 72/1722 89/1723 106/1723 123/1723 390/6891
Model 12 1 1.25 (0.91, 1.70) 1.50 (1.11, 2.02) 1.94 (1.45, 2.59) <0.001 1.28 (1.16, 1.42) <0.001
Model 23 1 1.31 (0.94, 1.84) 1.53 (1.11, 2.12) 1.88 (1.37, 2.59) <0.001 1.27 (1.14, 1.42) <0.001
Model 34 1 1.33 (0.95, 1.86) 1.56 (1.12, 2.16) 1.97 (1.42, 2.73) <0.001 1.29 (1.15, 1.45) <0.001
Ischemic stroke
Cases/n 48/1722 62/1723 80/1723 89/1723 279/6891
Model 12 1 1.30 (0.89, 1.89) 1.69 (1.18, 2.42) 2.07 (1.46, 2.94) <0.001 1.31 (1.16, 1.48) <0.001
Model 23 1 1.31 (0.88, 1.97) 1.66 (1.13, 2.44) 1.95 (1.33, 2.86) <0.001 1.28 (1.12, 1.46) <0.001
Model 34 1 1.33 (0.89, 1.99) 1.71 (1.16, 2.52) 2.09 (1.42, 3.09) <0.001 1.31 (1.15, 1.50) <0.001
1Cox proportional hazards regression models were used to calculate the HRs and 95% CIs. eGFR, estimated glomerular filtration rate; HUSK, Hordaland
Health Study; PAr, 4-pyridoxic acid /(pyridoxal + pyridoxal-5′-phosphate).
2Model 1 was adjusted for age (46-49 y vs. 70–74 y) and sex.
3Model 2 was adjusted as for model 1 plus BMI (continuous), current smoking (yes or no), education (≤10, 11–13, or ≥14 y) and physical activity
(none/light or moderate/vigorous).
4Model 3 was adjusted as for model 2 plus eGFR (continuous), hypertension (yes or no), diabetes (yes or no), total cholesterol (continuous), and statin
use (yes or no).
As shown inTable 2, higher levels of PArwere significantly as-
sociated with an increased risk of total stroke and ischemic stroke
in models adjusted for age and sex, in models with further adjust-
ments for BMI, current smoking, education, and physical activ-
ity, and in fully adjusted models with additional adjustments for
eGFR, hypertension, diabetes, total cholesterol, and statin use.
The multivariable-adjusted HR for total stroke was 1.29 (95%
CI: 1.15, 1.45) per 1-SD increment of log-transformed PAr, and
1.97 (95% CI: 1.42, 2.73, P-trend <0.001) for the highest com-
pared with the lowest PAr quartile. Additional adjustments for
CRP (HR/SD: 1.26, 95%CI: 1.11, 1.42), neopterin (HR/SD: 1.27,
95%CI: 1.12, 1.43), vitamin B-6 supplementation (HR/SD: 1.29,
95% CI: 1.15, 1.45) and fasting status (HR/SD: 1.29, 95% CI:
1.15, 1.45) did not materially affect the risk associations. Vita-
min B-6 supplementation was not associated with the risk of total
stroke (multivariable-adjusted HR/SD: 1.11, 95%CI: 0.74, 1.68).
Similar risk estimates were found for ischemic stroke (Table 2).
Generalized additive model plots showed that the association be-
tween PAr and risk of total and ischemic stroke was essentially
linear across the distribution of PAr values (Figure 2). When the
components of the PAr index, i.e., PA, pyridoxal, and PLP, were
evaluated separately, we found only a weak and positive associa-
tion for PA, and nonsignificant associations for PLP or pyridoxal
(data not shown).
The associations between PAr and the risk of total stroke were
similar in subgroups stratified by age, sex, BMI, current smok-
ing, hypertension, diabetes, and statin use at baseline (all P for
interaction >0.30, Table 3).
In sensitivity analyses, restricting the study population to the
6322 participants without self-reported history of CHD yielded
slightly attenuated associations for total stroke (HR/SD: 1.26,
95% CI: 1.11, 1.42) and ischemic stroke (HR/SD: 1.28, 95%
CI: 1.11, 1.49). The risk estimates for total stroke remained un-
changed after excluding 113 participants with self-reported his-
tory of stroke (HR/SD: 1.29, 95% CI: 1.15, 1.45). In addition,
repeating the analyses among the whole study cohort after ex-
cluding the first 2 y of follow-up yielded similar results (HR/SD:
1.29, 95% CI: 1.14, 1.46).
We compared PAr to all potential risk predictors included
in model 3 as well as CRP and neopterin by analyzing how
much they improved the model fit after being added to a Cox
regression model that included age and sex (Table 4). PAr
was the strongest predictor followed by CRP, current smok-
ing, diabetes, hypertension, eGFR, and physical activity among
all the 12 potential risk predictors. Forward stepwise selec-
tion identified PAr, diabetes, and current smoking, in that or-
der, as the best model for predicting total stroke, whereas in-
flammatory markers CRP and neopterin, among others, were
not selected (Table 4). In reclassification analysis, the addi-
tion of PAr to the fully adjusted model (model 3 in Table 2)
resulted in significant net reclassification improvement. The
category-free net reclassification index for the addition of PAr
in predicting total stroke was 0.184 (95% CI: 0.075, 0.294,
P = 0.001). Similarly, the corresponding integrated discrimina-
tion index was 0.004 (95% CI: 0.001, 0.006, P = 0.003).
DISCUSSION
Principal findings
In this prospective community-based study, we observed that
high plasma PAr, an indicator of altered vitamin B-6 homeostasis,
was associated with an increased risk of total and ischemic stroke.
The multivariable-adjusted risk estimates for stroke were almost
twice as high for participants in the highest compared with the
lowest quartile of PAr. The association between PAr and stroke
risk appeared to be independent of potential confounding factors,
CRP, and neopterin, and was similar across subgroups stratified
by age, sex, BMI, current smoking, hypertension, diabetes, or
statin use at baseline. Notably, PAr was the strongest predictor
of stroke risk among a panel of 12 potential risk factors when
evaluated by Cox regression and stepwise selection criteria.
PAr and stroke risk
We found that PAr was positively associated with stroke
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FIGURE 2 The associations of PAr with total and ischemic stroke by generalized additive models (n = 6891). The models were adjusted for age (46–49
vs. 70–74 y), sex, BMI (continuous), current smoking (yes or no), education (≤10, 11–13, or≥14 y), physical activity (none/light or moderate/vigorous), eGFR
(continuous), hypertension (yes or no), diabetes (yes or no), total cholesterol (continuous), and statin use (yes or no). The solid lines show HRs and the shaded
areas 95% CIs. The dashed lines show HRs by linear regression on logarithmic scale. Density plots indicate the distributions of log-transformed PAr, and dotted
lines denote the 10th, 50th, and 90th percentiles. eGFR, estimated glomerular filtration rate; PAr, 4-pyridoxic acid/(pyridoxal + pyridoxal-5′-phosphate).
distribution of PAr levels. Participants in the highest age-specific
quartile of PAr had an approximately double risk of total or is-
chemic stroke compared with those in the first quartile. The asso-
ciations between PAr and stroke were essentially unaltered in 3
models with gradual adjustments for age, sex, and other potential
confounding factors, and did not differ significantly between the
various subgroups. This indicates that the association is unlikely
to be mediated through traditional risk factors for stroke, such as
high BMI, smoking, hypertension, and diabetes (3). In addition,
vitamin B-6 supplementation was not associated with stroke risk.
Fasting status appeared to have negligible effect on PAr and its
risk associations.
The weak or nonsignificant risk associations for the compo-
nents of PAr (PLP, pyridoxal, and PA) suggest a minor role of vi-
tamin B-6 status (PLP). Apparently, inflammatory processes are
more important. Assuming a simultaneous influence of inflam-
mation on PA (increasing) and PLP+ pyridoxal (decreasing), the
PAr index is ideally configured to capture both processes.
Notably, PAr was found to be a stronger predictor of stroke
risk than the other inflammatory markers CRP and neopterin as
well as other potential risk predictors such as current smoking,
diabetes, hypertension, and eGFR, which closely resembles the
reported findings on PAr and all-cause mortality (17).
Causation and sensitivity analyses
Reverse causality (i.e., preclinical conditions before a diagno-
sis of stroke could lead to higher levels of PAr) needs attention
in observational studies. However, this was probably not the case
in our study as indicated by essentially unaltered risk estimates
after exclusion of the first 2 y of follow-up. Moreover, only mini-
mal changes in risk estimates were observed when restricting the
study population to those without self-reported history of CHD
or stroke at baseline. Taken together, these findings all attest to
the robustness and independence of PAr as a marker of stroke
risk.
Possible mechanisms
Systemic inflammation is strongly linked to the occurrence
of stroke, exacerbates ischemic brain damage, and shapes stroke
outcome (4, 5, 34). Although not yet fully elucidated, diverse in-
flammatory processes may trigger a stroke event through a va-
riety of mechanisms, including thrombosis through the coagu-
lation system (5), microvascular injury, and disturbed vascular
homeostasis (34), and by promoting atherosclerosis (5). In ad-
dition, immune activation due to systemic inflammatory condi-
tions or infection has a detrimental role in stroke pathophysiology
(34, 35).
Inflammation links closely with oxidative and aldehydes
stress, i.e., increased production of reactive oxygen species and
reactive aldehydes (36). In response, aldehyde-scavenging en-
zymes, including enzymes that catalyze the irreversible catabolic
conversion of PLP (via pyridoxal) to PA, are upregulated, leading
to an increase in PAr (13). In addition, other independent inflam-
matory processes lead to an increased uptake or retention of PLP
in tissues (12). As PLP appears in the denominator of PAr, these
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TABLE 3
PAr and risk of total stroke by strata in the HUSK1
Cases/n HR (95% CI) P-interaction
Age 0.54
46–49 y 37/3655 1.46 (1.01, 2.09)
70–74 y 353/3236 1.28 (1.13, 1.44)
Sex 0.69
Men 193/3036 1.30 (1.11, 1.54)
Women 197/3855 1.28 (1.09, 1.51)
BMI (kg/m2) 0.35
<25 157/3114 1.35 (1.14, 1.62)
≥25 233/3766 1.26 (1.08, 1.46)
Current smoking 0.78
No 296/4917 1.29 (1.12, 1.47)
Yes 94/1974 1.29 (1.03, 1.61)
Hypertension 0.61
No 121/3974 1.29 (1.05, 1.60)
Yes 269/2915 1.29 (1.12, 1.48)
Diabetes 0.58
No 358/6708 1.28 (1.14, 1.45)
Yes 32/183 1.35 (0.92, 1.98)
Statin use 0.52
No 347/6398 1.32 (1.16, 1.49)
Yes 43/493 1.18 (0.82, 1.69)
1HRs (95% CIs) are reported per 1-SD increment of log-transformed
PAr. Multivariate adjusted model: adjusted for age (46–49 vs. 70–74 y), sex,
BMI (continuous), current smoking (yes or no), education (≤10, 11–13, or
≥14 y), physical activity (none/light or moderate/vigorous), eGFR (contin-
uous), hypertension (yes or no), diabetes (yes or no), total cholesterol (con-
tinuous), and statin use (yes or no). eGFR, estimated glomerular filtration
rate; HUSK, Hordaland Health Study; PAr, 4-pyridoxic acid/(pyridoxal +
pyridoxal-5′-phosphate).
In our study, the association between PAr and stroke risk was
independent of CRP, a commonly used systemic marker of in-
flammation. This clearly suggests that inflammatory processes
forming the basis for the observed association of PAr with stroke
is not fully captured by CRP.
In addition, conventional risk factors, including aging, high
BMI, smoking, hypertension, and diabetes (4), are often accom-
panied by an inflammatory response, characterized by altered
glial activity and production of pro- and anti-inflammatory cy-
tokines (34). However, the association of PAr with stroke risk was
similar across subgroups stratified by age, BMI, smoking, hyper-
tension, and diabetes, indicating that PAr and these factors are
essentially mutually independent risk predictors and suggesting
that PAr is an indicator of aspects of the inflammatory response
beyond those elicited by the conventional risk factors.
Strengths and limitations
To the best of our knowledge, this is the first study to inves-
tigate altered vitamin B-6 homeostasis and stroke risk, allowing
a more comprehensive evaluation and understanding of vitamin
B-6 in relation to stroke. Other important strengths include the
prospective design, long and complete follow-up, and adjustment
for several possible confounders. Nevertheless, the true risk asso-
ciations may have been underestimated due to regression dilution
bias (37) because plasma biomarkers were measured at baseline
only. The comparatively high intraclass correlation coefficient of
PAr (0.75) (13), however, suggests that regression dilution bias
TABLE 4
Comparison of predictive strength for selected variables using AIC in the
HUSK (n = 6891) 1
AIC Order of strength2 Order of selection3
PAr –16.7 1 1
Diabetes –8.1 4 2
Current smoking –8.2 3 3
Hypertension –5.1 5 NA
eGFR –0.1 6 NA
CRP –8.7 2 NA
Physical activity 1.2 7 NA
1AIC calculated as reduction in the AIC after the inclusion of the
variable in a Cox regression model that was adjusted for age and sex. The
AIC for the starting model was 5111.7. Potential risk predictors include: PAr
(log transformed), CRP (log transformed), neopterin (log transformed), age
(46–49 y vs. 70–74 y), sex, BMI (continuous), current smoking (yes or no),
education (≤10, 11–13, or ≥14 y), physical activity (none/light or moder-
ate/vigorous), eGFR (continuous), hypertension (yes or no), diabetes (yes or
no), total cholesterol (continuous), and statin use (yes or no). AIC, Akaike’s
information criterion; CRP, C-reactive protein; eGFR, estimated glomerular
filtration rate; HUSK, Hordaland Health Study; NA, not applicable; PAr, 4-
pyridoxic acid/(pyridoxal + pyridoxal-5′-phosphate).
2Order of predictive strength according to the AIC.
3Order of selection in a Cox regression model with the use of forward
stepwise selection. Age and sex as adjustments at all times.
probably plays a minor role in the evaluation of PAr with the risk
of stroke.
In conclusion, we observed that plasma levels of PAr, a mul-
tifactorial indicator of cellular immunity activation, oxidative
stress, and related inflammatory responses, have a continuous and
independent association with the risk of total and ischemic stroke
in community-dwelling men and women. As a risk predictor of
stroke, PAr was superior to the established inflammatory markers
CRP and neopterin, but also to a complete panel of conventional
risk factors of stroke including smoking and diabetes. Our find-
ings highlight inflammation and immunity in the pathogenesis of
stroke and point at limitations of established inflammatory mark-
ers. Finally, our results suggest additional reaction mechanisms
and pathways, some of them apparently captured by the PAr in-
dex, which merit greater attention in further studies for the ulti-
mate translation into effective preventive measures for stroke in
the future.
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